1. Home
  2. FET vs RIGL Comparison

FET vs RIGL Comparison

Compare FET & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FET
  • RIGL
  • Stock Information
  • Founded
  • FET 2005
  • RIGL 1996
  • Country
  • FET United States
  • RIGL United States
  • Employees
  • FET N/A
  • RIGL N/A
  • Industry
  • FET Metal Fabrications
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FET Industrials
  • RIGL Health Care
  • Exchange
  • FET Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • FET 209.6M
  • RIGL 247.1M
  • IPO Year
  • FET 2012
  • RIGL 2000
  • Fundamental
  • Price
  • FET $14.90
  • RIGL $25.04
  • Analyst Decision
  • FET
  • RIGL Buy
  • Analyst Count
  • FET 0
  • RIGL 5
  • Target Price
  • FET N/A
  • RIGL $31.30
  • AVG Volume (30 Days)
  • FET 49.3K
  • RIGL 288.9K
  • Earning Date
  • FET 10-31-2024
  • RIGL 11-07-2024
  • Dividend Yield
  • FET N/A
  • RIGL N/A
  • EPS Growth
  • FET N/A
  • RIGL N/A
  • EPS
  • FET N/A
  • RIGL 0.22
  • Revenue
  • FET $800,612,000.00
  • RIGL $157,374,000.00
  • Revenue This Year
  • FET $12.53
  • RIGL $38.26
  • Revenue Next Year
  • FET $1.54
  • RIGL $24.21
  • P/E Ratio
  • FET N/A
  • RIGL $109.79
  • Revenue Growth
  • FET 7.56
  • RIGL 21.65
  • 52 Week Low
  • FET $12.83
  • RIGL $7.48
  • 52 Week High
  • FET $23.82
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • FET 46.65
  • RIGL 68.80
  • Support Level
  • FET $14.25
  • RIGL $22.33
  • Resistance Level
  • FET $15.50
  • RIGL $29.16
  • Average True Range (ATR)
  • FET 0.54
  • RIGL 2.30
  • MACD
  • FET -0.02
  • RIGL 0.41
  • Stochastic Oscillator
  • FET 36.88
  • RIGL 69.96

About FET Forum Energy Technologies Inc.

Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in three reporting segments, namely drilling and downhole which is also its key revenue generating segment, completions, and production. Revenue largely comes from consumable products and activity-based equipment. Consumable products include valves, centrifugal pumps, mud pump fluid end components, rig sensors among others.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: